巨子生物
GIANT BIOGENE

GIANT BIOGENE HOLDING CO., LTD
巨 子 生 物 控 股 有 限 公 司

(An exempted company incorporated in the Cayman Islands with limited liability)

(Stock code: 2367)

VOLUNTARY ANNOUNCEMENT PROPOSED SHARE REPURCHASE UNDER THE SHARE REPURCHASE MANDATE

This announcement is made by Giant Biogene Holding Co., Ltd (the "**Company**" together with its subsidiaries, the "**Group**") on a voluntary basis.

References are made to the circular (the "**Circular**") of the Annual General Meeting of the Company dated 29 April 2025 and the announcement (the "**Announcement**") of the poll results of the Annual General Meeting dated 13 June 2025 in relation to, among other things, the proposed grant of the general mandate to repurchase shares. Unless the context otherwise requires, terms used herein shall have the same meanings as those defined in the Circular and the Announcement.

The board of directors (the "**Board**") of the Company hereby announces that it intends to exercise the powers under the general mandate to repurchase shares of the Company granted by the Shareholders to the Directors by the resolution of the shareholders passed at the Annual General Meeting of the Company held on 13 June 2025. Pursuant to the Share Repurchase Mandate, the Company is allowed to repurchase up to 103,590,400 shares, being 10% of the number of issued Shares (excluding treasury shares) as at the date of the resolution passed at the Annual General Meeting. The Mandate will expire at the earliest of: (i) the conclusion of the next annual general meeting of the Company; or (ii) the expiration of the period within which the next annual general meeting of the Company is required by the Articles of the Company or other applicable laws to be held; or (iii) the date on which the mandate to repurchase shares is revoked or varied by an ordinary resolution of the shareholders at general meeting.

The Company intends to use its own funds to finance the abovementioned Share Repurchase scheme, and the implementation of such scheme is not expected to have any material adverse impact on the working capital position of the Group. The Board believes that the current share price is lower than its intrinsic value, which does not fully reflect the business prospects and asset value of the Company. The Share Repurchase scheme reflects the confidence of the Board and the management team in the long-term strategy and growth of the Group. Moreover, the Share Repurchase scheme will also enhance financial indicators such as earnings per share. The Board considers that the Share Repurchase scheme is in the interest of the Company and the Shareholders as a whole, and is an effective measure for capital management and optimization of capital structure.

The implementation of the Share Repurchase scheme will be subject to compliance with the Share Repurchase Mandate, the Articles of Association, the Listing Rules, The Codes on Takeovers and Mergers and Share Repurchases, the laws of the Cayman Islands and applicable laws and regulations relating to the repurchase of shares by the Company. Any Shares repurchased under the Share Repurchase scheme will be cancelled and/or held as treasury shares in due course.

Shareholders and investors should note that implementation of the Share Repurchase scheme by the Company will be subject to market conditions and will be at the Board's absolute discretion. There is no assurance of the timing, quantity or price of any Share repurchases or whether the Company will make any repurchases at all. Shareholders and investors should therefore exercise caution when dealing in the Shares.

By order of the Board
Giant Biogene Holding Co., Ltd
Yan Jianya
Chairman of the Board

Xi'an, the PRC, 2 December 2025

As of the date of this announcement, the Board comprises Mr. Yan Jianya, Ms. Ye Juan, Ms. Fang Juan, Ms. Zhang Huijuan and Ms. Yan Yubo as executive directors, and Mr. Huang Jin, Mr. Shan Wenhua and Ms. Wong Sze Wing as independent non-executive directors.